\-\ Texto\\:\\ \ \(0\)\
\-\ pulmonary\\ \\-\\ bilbasilar\\ rhonci\\,\\ increased\\ sob\ \(0\)\
\-\ cbc\\ \\-\\ 5\\.2\\/13\\.8\\/40\\.9\\/241\ \(0\)\
\-\ bmp\\ \\-\\ 145\\/3\\.4\\/104\\/31\\/13\\/1\\.0\\/87\ \(0\)\
\-\ ck\\ \\-\\ 104\ \(0\)\
\-\ high\\ dose\\ prednisone\\ 1\\ mg\\/kg\ \(0\)\
\-\ methotrexate\ \(25\)\
\-\ pulmonary\\ fibrosis\\ in\\ a\\ bibasilar\\ pattern\\.\\ \\ characterisitc\\ honeycomb\\ pattern\\ commonly\\ seen\\ in\\ interstitial\\ lung\\ disease\\.\ \(0\)\
\-\ interstitial\\ lung\\ disease\ \(17\)\
\-\ dermatomyositis\\ \ \(2\)\
\-\ other\\ connective\\ tissue\\ disease\ \(1\)\
\-\ asbestos\ \(71\)\
\-\ radiation\ \(402\)\
\-\ medication\\ side\\ effect\ \(1\)\
\-\ 63\\ yo\\ male\\ with\\ hx\\ of\\ dermatomyositis\\ c\\/o\\ increased\\ sob\ \(0\)\
\-\ interstitial\\ lung\\ disease\\ is\\ seen\\ in\\ approximately\\ 10\\%\\ of\\ cases\\ of\\ dermatomyositis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ dermatomyositis\\:\\ 0\\.24989257003336174\ \(0\)\
\-\ interstitial\\:\\ 0\\.1650311619369814\ \(0\)\
\-\ sob\\:\\ 0\\.13123360598624745\ \(0\)\
\-\ bilbasilar\\:\\ 0\\.11599366347324339\ \(0\)\
\-\ 5\\.2\\/13\\.8\\/40\\.9\\/241\\:\\ 0\\.11599366347324339\ \(0\)\
\-\ 145\\/3\\.4\\/104\\/31\\/13\\/1\\.0\\/87\\:\\ 0\\.11599366347324339\ \(0\)\
\-\ characterisitc\\:\\ 0\\.11599366347324339\ \(0\)\
\-\ rhonci\\:\\ 0\\.10687330583429674\ \(0\)\
\-\ mg\\/kg\\:\\ 0\\.1015382386223472\ \(0\)\
\-\ lung\\:\\ 0\\.09770364948310839\ \(0\)\
\-\ \\-\\:\\ 0\\.0964067609846507\ \(0\)\
\-\ honeycomb\\:\\ 0\\.09038958256462085\ \(0\)\
\-\ pattern\\:\\ 0\\.08595900892292838\ \(0\)\
\-\ ck\\:\\ 0\\.08329752334445391\ \(0\)\
\-\ 104\\:\\ 0\\.0795122329174568\ \(0\)\
\-\ asbestos\\:\\ 0\\.07473716063207038\ \(0\)\
\-\ bmp\\:\\ 0\\.07417716570550727\ \(0\)\
\-\ disease\\:\\ 0\\.07351250216924758\ \(0\)\
\-\ bibasilar\\:\\ 0\\.07262738892055486\ \(0\)\
\-\ methotrexate\\:\\ 0\\.07168713939447399\ \(0\)\
\-\ prednisone\\:\\ 0\\.06650418826674914\ \(0\)\
\-\ connective\\:\\ 0\\.06620169460589785\ \(0\)\
\-\ c\\/o\\:\\ 0\\.06590599913416025\ \(0\)\
\-\ pulmonary\\:\\ 0\\.06569869237421219\ \(0\)\
\-\ 63\\:\\ 0\\.062341855000799716\ \(0\)\
\-\ dose\\:\\ 0\\.05883832897516861\ \(0\)\
\-\ medication\\:\\ 0\\.05664024891381116\ \(0\)\
\-\ hx\\:\\ 0\\.05566514401705166\ \(0\)\
\-\ increased\\:\\ 0\\.05501275741578041\ \(0\)\
\-\ cbc\\:\\ 0\\.05024087039739977\ \(0\)\
\-\ fibrosis\\:\\ 0\\.05006425170881897\ \(0\)\
\-\ seen\\:\\ 0\\.04443756881757079\ \(0\)\
\-\ commonly\\:\\ 0\\.04242804530862686\ \(0\)\
\-\ effect\\:\\ 0\\.039809977014069006\ \(0\)\
\-\ side\\:\\ 0\\.03895324344426409\ \(0\)\
\-\ 10\\:\\ 0\\.03790295037298566\ \(0\)\
\-\ cases\\:\\ 0\\.03745803768396227\ \(0\)\
\-\ radiation\\:\\ 0\\.03689804275739916\ \(0\)\
\-\ approximately\\:\\ 0\\.03478707666520504\ \(0\)\
\-\ yo\\:\\ 0\\.03383357267503634\ \(0\)\
\-\ high\\:\\ 0\\.030770342908905467\ \(0\)\
\-\ 1\\:\\ 0\\.0267542943152593\ \(0\)\
\-\ tissue\\:\\ 0\\.02665027879542886\ \(0\)\
\-\ \\%\\:\\ 0\\.0262279083335001\ \(0\)\
\-\ other\\:\\ 0\\.02591629669345327\ \(0\)\
\-\ male\\:\\ 0\\.020331651814308856\ \(0\)\
\-\ in\\:\\ 0\\.016634101189746904\ \(0\)\
\-\ is\\:\\ 0\\.007398562873483232\ \(0\)\
\-\ a\\:\\ 0\\.005218418444981596\ \(0\)\
\-\ of\\:\\ 0\\.004598834242025859\ \(0\)\
\-\ \\,\\:\\ 0\\.003561974546280097\ \(0\)\
\-\ with\\:\\ 0\\.001539528632761707\ \(0\)\
\-\ \\.\\:\\ 0\\.0014012974775268266\ \(0\)\
